Researchers Submit Patent Application, "Transient Protection Of Normal Cells During Chemotherapy", for Approval (USPTO 20230381189).
In: Pharma Business Week, 2023-12-18, S. 1388-1388
serialPeriodical
Zugriff:
G1 Therapeutics Inc. has submitted a patent application for a method to protect normal cells during chemotherapy. The method involves using CDK4/6 inhibitors to minimize the toxicity of chemotherapy on healthy cells, specifically hematopoietic stem cells, hematopoietic progenitor cells, and renal epithelial cells. This method aims to reduce the need for dose reductions or delays in chemotherapy, which can compromise treatment effectiveness. The patent application provides specific examples of compounds and chemotherapeutic agents that can be used in the method, and highlights its potential benefits for treating triple negative breast cancer and reducing chemotherapy-induced myelosuppression in bladder cancer patients. [Extracted from the article]
Copyright of Pharma Business Week is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Researchers Submit Patent Application, "Transient Protection Of Normal Cells During Chemotherapy", for Approval (USPTO 20230381189).
|
---|---|
Zeitschrift: | Pharma Business Week, 2023-12-18, S. 1388-1388 |
Veröffentlichung: | 2023 |
Medientyp: | serialPeriodical |
ISSN: | 1543-6675 (print) |
Schlagwort: |
|
Sonstiges: |
|